Abstract
Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.
Original language | English |
---|---|
Pages (from-to) | 1201-1204 |
Number of pages | 4 |
Journal | The oncologist |
Volume | 14 |
Issue number | 12 |
DOIs | |
Publication status | Published - 2009 |
Keywords
- Bullous dermatitis
- Case report
- Erlotinib
- Skin toxicity
ASJC Scopus subject areas
- Cancer Research
- Oncology